Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 muscle tone, placebo-controlled, cross-over study of Nabiximols in patients with Multiple Sclerosis spasticity(nabiximols responders)

Next Previous
Search
Trial Profile

A Phase 3 muscle tone, placebo-controlled, cross-over study of Nabiximols in patients with Multiple Sclerosis spasticity(nabiximols responders)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Muscle spasticity
  • Focus Registrational; Therapeutic Use
  • Sponsors GW Pharmaceuticals

    • Most Recent Events

    • 16 Feb 2021 According to a GW Pharmaceuticals media releases, this trial is expected to start in Q2 2021.
    • 06 Jul 2020 New trial record
    • 30 Jun 2020 According to a GW Pharmaceuticals media release, the company will host a webcast today to provide insight into the U.S. Phase 3 clinical program and commercial opportunity for nabiximols.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top